IBJNews

Lilly's Cymbalta wins new approval for anxiety disorder

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co. announced Monday that it has won approval to market star drug Cymbalta for a new use, an event likely to boost sales of the medicine.

The U.S. Food and Drug Administration OK’d Cymbalta as a maintenance treatment for generalized anxiety disorder, which affects nearly 7 million Americans. Cymbalta was already approved to treat acute attacks of generalized anxiety disorder, but the approval as a maintenance therapy means patients can take the drug on a regular basis.

Many physicians have already been prescribing Cymbalta as a maintenance therapy for anxiety, but the FDA approval allows Lilly to specifically market Cymbalta for the new use.

Sales of Cymbalta, Lilly’s No. 2  selling drug, grew at a 13.6-percent clip through the first nine months of the year, and are on pace to top $3 billion for the year.

Lilly needs extra sales of Cymbalta to offset the looming loss of revenue when its cancer drug Evista and antipsychotic Zyprexa face competition from cheaper generics in 2010 and 2011, respectively.

Cymbalta, which was first approved as an antidepressant in 2004, is now also approved to treat diabetic neuropathy and fibromyalgia, all in adults.

ADVERTISEMENT

  • Zyprexa profits
    Eli Lilly has been around for a century,and a proven performer.I am waiting to see how they resolve the costly Zyprexa saga.

    Great news that Eli Lilly is posting profit,as a Zyprexa damage claimant who got diabetes from it I know that Lilly can afford to pay me my settlement.

    ----
    Daniel Haszard

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT